Introduction
Introduction

Erythropoietin (EPO) is a hypoxia-induced glycoprotein hormone that stimulates the proliferation and differentiation of erythroid precursor cells in order to counteract diminished oxygen levels, including those caused by anaemia and hypoxia
. It can inhibit hypoxia-induced apoptosis of cardiomyocytes and protect cardiomyoblasts from hydrogen peroxideinduced injury [3] [4] [5] . EPO can also induce neo-vascularization [6] , reduce the infarction size and confer effective cardiac protection against ischaemia-reperfusion injury and chronic heart failure [7] [8] [9] [10] . This combined evidence has fuelled significant interest in the potential use of EPO as a cytoprotective agent in the cardiovascular system. Fig. 1A and B) . However, RV dp/dt max did not significantly differ between the two groups (P ϭ 0.199). MI-EPO hearts responded to dobutamine stress with a significant increase in heart rate (P ϭ 0.019, 
Intracardiac injection of erythropoietin induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model
Haematological, biochemical and FACS analysis of peripheral blood
Analysis of peripheral blood from the right ventricle (MIC and MI-EPO groups) were performed at 24 hrs (n ϭ 7, for each group), 48 hrs (n ϭ 7) and 2 weeks (n ϭ 5) after MI. Haematocrit was examined by Sysmex XE-2100 (SYSMEX, Norderstedt, Germany
Determination of capillary density
Capillary density was assessed at 6 weeks after surgery by counting the number of capillaries of the heart sections immunostained with polyclonal goat anti-CD31 primary antibody followed by donkey anti-goat
Results
Local EPO delivery improves cardiac functions
Local EPO delivery reduces infarction size, inhibits cardiac remodelling and cardiomyocytes apoptosis
Computerized planimetry of the heart cross-sections revealed that scar area was remarkably lower in MI-EPO than in MIC ( Fig. 2A  and B (Fig. 2L-N) . Quantitative
real-time PCR revealed a 3-fold increase in mRNA expression of pro-survival Bcl2 gene after 6 weeks in the non-infarcted myocardium of MI-EPO hearts compared with MIC hearts (P ϭ 0.001, Fig. 2O).
Local EPO delivery promotes neoangiogenesis
Capillary density was analysed by immunostaining with an anti-CD31 antibody (Fig. 3A) . Capillary density was significantly higher in both zones for rats that received EPO (border zone: P Ͻ 0.001; RA: P ϭ 0.009, Fig. 3B ). There was no sign of intramural thrombosis after EPO injection. Fig. 6A 
Local EPO delivery up-regulates SDF-1, CXCR4 and MMP-2 expression
We examined whether EPO treatment altered SDF-1, CXCR4 and MMP2 expression by immunostaining and real-time PCR. Quantitative real-time PCR revealed SDF-1 mRNA was significantly up-regulated in MI-EPO hearts (P Ͻ 0.05, Fig. 4A) at 24 hrs in both IZ and NIZ compared with MIC. These data were further corroborated by immunostaining of SDF-1, which identified a clear SDF-1 expression pattern in MI-EPO hearts: in NIZ, SDF-1 was detected in the endothelial cells bordering the vessel lumen (Fig. 4D-G). In IZ, SDF-1 was detected in interstitial cells and endothelial cells (Fig. 4H and I). More abundant SDF-1 signals were detected in IZ of MI-EPO hearts compared with MIC (Fig. 4J and K). Furthermore, the mRNA of CXCR-4 and matrix metalloproteinase 2 (MMP-2) augmented at 24 hrs in NIZ. In IZ, the CXCR4 and MMP-2 mRNA levels did not differ between MIC and MI-EPO (Fig. 4B and C).
Local EPO delivery augments sequential myocardial stem cell recruitment
Local EPO delivery induces survival pathways
To clarify cardioprotective effects of EPO, quantitative real-time PCR was applied to evaluate mRNA levels of eNOS and Akt, known to be involved in various steps of anti-inflammation, anti-apoptosis and myocyte survival. As shown in
and B, mRNA levels of Akt and eNOS were up-regulated in both IZ and NIZ at 24 and 48 hrs in response to EPO treatment (P Ͻ 0.05). Thus, the cardioprotective effects of direct EPO injection may be associated with the up-regulation of tissue protective factors like Akt and eNOS.
Local EPO delivery up-regulates EPO receptor
We performed real-time PCR to estimate the effect of direct EPO injections on EPO-R in cardiac tissue. EPO-R mRNA of MI-EPO was significantly up-regulated in IZ at 24 hrs, and in NIZ at both 24 and 48 hrs as compared with MIC (P Ͻ 0.05, Fig. 6C).
Local EPO delivery mobilizes stem/progenitor cells to peripheral blood
Fig. 4 Direct EPO injection up-regulates SDF-1, CXCR4 and MMP2. (A-C) Quantitative real-time PCR analysis for SDF-1 (A), CXCR4 (B) and MMP2 (C) genes, respectively, in IZ and NIZ of MI-EPO (n ϭ 7), MIC (n ϭ 7) and Sham (n ϭ 7) hearts. The average mRNA expression level in the sham hearts was arbitrarily given a value of 1 (2Њ). *P Ͻ 0.05. (D-I) Representative confocal microscopic images illustrating different expression patterns of SDF-1 in MI-EPO. (D-G) In NIZ of MI-EPO, most SDF-1 ϩ cells (red) co-localized with CD31 (green). Occasionally, cell adhesion (arrows in F and G) with the
SDF-1 ϩ endothelial cells was visible. (H, I) In contrast, a number of SDF-1 ϩ cells (red) in IZ of MI-EPO hearts did not co-localize with CD31 (green).
Scale bars ϭ 10 m. [28] . Elevated RV loading [29, 30] . However, prolonged EPO exposure [31, 32] . In this study, EPO [11, 12, 15, 38] . Reports also suggest that stem cells could incorporate into sites of active neovascularization after myocardial ischaemia [13, 14, 16, 17] [44, 45] . The present data also confirm our previous finding that eNOS is crucial for SDF-1-mediated cKit ϩ HSC directional migration [46] . [48] , which suggests that EPO-R expression is independent of the EPO administration methods.
Others studies indicate that myocardial necrosis progresses within 6 hrs after the onset of MI [49, 50] and prompt reperfusion within this narrow time window significantly decreases early mortality [51] . Administration of EPO during the therapeutic window significantly reduces infarction size and improves cardiac function [3-5, 10, 32, 52] . Hence, local injection of EPO during emergency coronary artery bypass graft surgery after acute MI could be an optimal approach for EPO treatment.
In 
